Key facts
- It has raised $3.3M; the latest was Early Stage VC ($3.3M) in Apr 2025.
- Notable investors include Bpifrance, Bretagne Sud Angels, Business Angels 35, GwenneG, Societe Financiere Lorient Developpement.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CHENEVIA
- ·The full record, as it builds
Funding rounds
No funding rounds for CHENEVIA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CHENEVIA
Operator of a therapeutic biotechnology company intended to offer medical cannabis, compliant with Good Manufacturing Practices (GMP). The company produces optimal-quality medical cannabis flower under a fully controlled environment and incorporates responsible farming methods that preserve biodiversity, enabling research laboratories and pharmaceutical manufacturers to optimize their performance.
- Sector
- Healthcare
- HQ
- Meucon, France
- Founded
- 2021
- Employees
- 5
- Website
- chenevia-pharma.com/
- Ownership
- Privately Held (backing)
CHENEVIA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CHENEVIA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CHENEVIA in its N-PORT filings yet. We sweep new filings monthly.